StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63−0.05 (-7.21%)

Close on Nov 17, 2026Market cap $23.84MP/E –Yield –

Metagenomi Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Metagenomi Therapeutics's price to sales ratio was 2.0× on Jul 31, 2026, against 1.9× a year earlier. Over the last 3 years it ranged from 0.5× to 5.1×, with a median of 2.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 20262.0×+0.0
2025Dec 31, 20252.0×−0.5
2024Dec 31, 20242.5×–

More Metagenomi Therapeutics figures

See a number that looks wrong?